Our News on Newswise

MD Anderson celebrates World Cancer Research Day

The University of Texas MD Anderson Cancer Center again supports World Cancer Research Day, Sept. 24, and its goals to highlight the importance of cancer research, to promote scientific collaboration and to reduce the global burden of cancer through...
23-Sep-2022 11:00 AM EDT Add to Favorites

MD Anderson Research Highlights for September 14, 2022

The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts.
14-Sep-2022 12:00 PM EDT Add to Favorites

MD Anderson and Radiopharm Theranostics launch joint venture to develop novel radiopharmaceuticals

MD Anderson and Radiopharm Theranostics today announced the launch of Radiopharm Ventures, LLC, a joint venture created to develop novel radiopharmaceutical therapeutic products for cancer.
13-Sep-2022 7:00 PM EDT Add to Favorites

Newswise: 631e9b1f3c67c_Linghua-Wanglatest.jpg

Tumor-infiltrating B cells and plasma cells influence early-stage lung cancer biology, immunotherapy responses

MD Anderson researchers used extensive single-cell analysis to create a spatial map of tumor-infiltrating B cells and plasma cells in early-stage lung cancers, revealing new roles for these immune cells in cancer development and immunotherapy...
12-Sep-2022 8:00 AM EDT Add to Favorites

Newswise: 631f7a75b2bf3_viveksubbiah.jpg

RET inhibitor selpercatinib demonstrates durable responses in tumor-agnostic population

The highly selective RET inhibitor selpercatinib was well-tolerated and achieved durable objective responses across multiple tumor types in the Phase I/II LIBRETTO-001 trial.
12-Sep-2022 2:35 PM EDT Add to Favorites

Immunotherapy before surgery induces complete response in more than half of patients with common skin cancer in international study

In an international, multicenter Phase II clinical trial led by The University of Texas MD Anderson Cancer Center, 63.3% of patients with stage II–IV cutaneous squamous cell carcinoma (CSCC) saw their tumors nearly or completely disappear when...
10-Sep-2022 4:15 AM EDT Add to Favorites

Patients with refractory metastatic colorectal cancer experience survival benefits with fruquintinib

Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that the targeted therapy fruquintinib significantly improved overall survival (OS) and progression-free survival (PFS) in patients with refractory...
10-Sep-2022 12:05 PM EDT Add to Favorites

HER2-low metastatic breast cancer patients report preserved quality of life with trastuzumab deruxtecan treatment

Patients who received trastuzumab deruxtecan (T-DXd) for human epidermal growth factor receptor 2 (HER2)-low metastatic breast cancer reported that the treatment maintained their quality of life (QoL) compared to conventional chemotherapy, according...
9-Sep-2022 2:45 PM EDT Add to Favorites


See All News

Our Experts on Newswise

Newswise: BenjaminSmith.jpg

Mastectomy Plus Reconstruction Has Highest Rate of Complication, Complication-Related Costs of Guideline-Concordant Therapies for Early Breast Cancer

In a review of guideline-concordant treatment modalities for women with early stage breast cancer, mastectomy and reconstruction had the highest rate of complications and complication-related costs, regardless of age.
27-Sep-2016 3:05 PM EDT

Newswise: Liang_H_Bronto.jpg

Can Gender Play a Role in Determining Cancer Treatment Choices?

It is well known that men and women differ in terms of cancer susceptibility, survival and mortality, but exactly why this occurs at a molecular level has been poorly understood.
9-May-2016 12:00 PM EDT

Newswise: ZhiminLu.jpg

MD Anderson Study Reveals New Insight Into Tumor Progression

Scientists know that activation of growth factor receptors like epidermal growth factor receptors (EGFR) promote tumor progression in many types of cancer.
17-Aug-2015 11:00 AM EDT

Newswise: Lee_M.jpg

Poor Survival Among Colorectal Cancer Patients Tied to Biomarker CSN6

A protein called CSN6 has been found to be correlated with poor survival among patients with colorectal cancer, according to a study at The University of Texas MD Anderson Cancer Center.
10-Aug-2015 12:00 PM EDT

Newswise: 204929_Chhatwal_Jjpg.jpg

MD Anderson Study Predicts New Hepatitis C Drugs Will Place a Dramatic Financial Strain on the Health Care System

The cost of treating people infected with the hepatitis C virus (HCV) with newly approved therapies will likely place a tremendous economic burden on the country’s health care system. The prediction comes from a cost-effectiveness analysis led by...
16-Mar-2015 6:00 PM EDT

MD Anderson Joins CATCH Global Foundation to Boost Child Health, Prevent Cancer in Later Years

Cancer prevention experts at The University of Texas MD Anderson Cancer Center have allied with the CATCH Global Foundation, whose comprehensive child health program reaches children and their families in more than 10,000 educational settings...
18-Feb-2015 10:00 AM EST

MD Anderson Energy Balance Expert Available for Obesity, Cancer Stories

30-Oct-2013 8:10 PM EDT

MD Anderson Obesity and Cancer Expert Researches Food Addiction

30-Oct-2013 8:00 PM EDT

See All Experts

Our YouTube Videos

About

The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. The institution’s sole mission is to end cancer for patients and their families around the world. MD Anderson is one of only 53 comprehensive cancer centers designated by the National Cancer Institute (NCI). MD Anderson is No.1 for cancer in U.S. News & World Report’s “Best Hospitals” rankings, and has been named one of the nation’s top two hospitals for cancer since the rankings started in 1990. MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).

Contacts

Aubrey Bloom
Program Manager, Public Relations

ARBloom@mdanderson.org

830-377-8566

Clayton Boldt
Program Director, Public Relations

crboldt@mdanderson.org

713-792-9518

Katrina Burton
Program Manager, Public Relations

kburton@mdanderson.org

713-792-8034

Lany Kimmons
Program Manager, Public Relations

rlkimmons@mdanderson.org

713-563-5801

Julie Nagy
Program Manager, Public Relations

jenagy@mdanderson.org

713-563-3437

Meagan Raeke
Program Manager, Public Relations

meraeke@mdanderson.org

713-563-9340

Allison Schaffer
Program Manager, Public Relations

ASchaffer@mdanderson.org

713-745-1357

Jade Waddy
Program Manager, Public Relations

JAWaddy@mdanderson.org

346-725-2126

Twitter

close
0.46677